Compare CCI & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCI | EW |
|---|---|---|
| Founded | 1994 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4B | 50.2B |
| IPO Year | 1998 | 1999 |
| Metric | CCI | EW |
|---|---|---|
| Price | $86.45 | $84.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $106.67 | $96.47 |
| AVG Volume (30 Days) | 2.8M | ★ 4.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | ★ 111.25 | N/A |
| EPS | 1.01 | ★ 1.83 |
| Revenue | $4,264,000,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | $1.63 | $9.78 |
| P/E Ratio | $86.66 | ★ $46.57 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $77.89 | $65.94 |
| 52 Week High | $115.76 | $87.89 |
| Indicator | CCI | EW |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 55.46 |
| Support Level | $84.23 | $81.61 |
| Resistance Level | $88.28 | $87.22 |
| Average True Range (ATR) | 2.20 | 2.19 |
| MACD | -0.23 | 0.22 |
| Stochastic Oscillator | 15.89 | 69.95 |
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown Castle has plans to divest its fiber business, which is expected to be finalized in the first half of 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.